Clinical Trial Update: Efficacy, Safety and Tolerability Study of ND0612 vs. Oral Immediate Release Levodopa/Carbidopa (IR-LD/CD) in Subjects With Parkinson's Disease Experiencing Motor Fluctuations [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating efficacy, safety and tolerability of ND0612 versus immediate-release Levodopa/Carbidopa in Parkinson's disease patients with motor fluc…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• Levodopa/Carbidopa (levodopa/carbidopa)
• ND0612 (ND0612)

Snippet

Sponsor: NeuroDerm Ltd. | Conditions: Parkinson's Disease | Phase 3 | Status: ACTIVE_NOT_RECRUITING